Author

Aakanksha Khandelwal

Observed names: A Khandelwal, A. Khandelwal

Institutions: Homi Bhabha National Institute, Tata Memorial Hospital, Advanced Centre for Treatment, Research and Education in Cancer

Observed institutions: University of Maryland, Baltimore, United States Food and Drug Administration, Center for Drug Evaluation and Research, Merck KGaA, Darmstadt (Germany), Homi Bhabha National Institute, Tata Memorial Hospital, Advanced Centre for Treatment, Research and Education in Cancer, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

OpenAlex ID: A5031374166

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

2012 · R. Angelo de Claro, Karen McGinn, et al. · Clinical Cancer Research · 210

Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases

2006 · Vincent C.O. Njar, Lalji Gediya, et al. · Bioorganic & Medicinal Chemistry · 147

Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer

2008 · Tadas Vasaitis, Aashvini Belosay, et al. · Molecular Cancer Therapeutics · 135

PDF

Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts

2007 · Lalji K. Gediya, Aashvini Belosay, et al. · Bioorganic & Medicinal Chemistry · 51

2021 · Kerry L Reynolds, Shaily Arora, et al. · Journal for ImmunoTherapy of Cancer · 47

PDF

Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth

2007 · J B Patel, J Mehta, et al. · British Journal of Cancer · 44

PDF

Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent

2008 · Puranik Purushottamachar, Aakanksha Khandelwal, et al. · Bioorganic & Medicinal Chemistry · 39

U.S. Food and Drug Administration Approval: Rituximab in Combination with Fludarabine and Cyclophosphamide for the Treatment of Patients with Chronic Lymphocytic Leukemia

2011 · Sandra J. Casak, Steven J. Lemery, et al. · The Oncologist · 38

Design, Synthesis, and Evaluation of Novel Mutual Prodrugs (Hybrid Drugs) of All-trans-Retinoic Acid and Histone Deacetylase Inhibitors with Enhanced Anticancer Activities in Breast and Prostate Cancer Cells in Vitro

2008 · Lalji K. Gediya, Aakanksha Khandelwal, et al. · Journal of Medicinal Chemistry · 37

First pharmacophore-based identification of androgen receptor down-regulating agents: Discovery of potent anti-prostate cancer agents

2007 · Puranik Purushottamachar, Aakanksha Khandelwal, et al. · Bioorganic & Medicinal Chemistry · 28

A novel pro-oxidant combination of resveratrol and copper reduces transplant related toxicities in patients receiving high dose melphalan for multiple myeloma (RESCU 001)

2022 · Anshul Agarwal, Aakanksha Khandelwal, et al. · PLoS ONE · 24

PDF

MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours

2008 · A Khandelwal, L K Gediya, et al. · British Journal of Cancer · 19

PDF

Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents

2007 · Jyoti B. Patel, Aakanksha Khandelwal, et al. · Cancer Chemotherapy and Pharmacology · 10

VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats

2014 · Abhijit M. Godbole, Senthilmurugan Ramalingam, et al. · European Journal of Pharmacology · 6

Antibody–Drug Conjugate Development

2012 · Aakanksha Khandelwal, Haleh Saber, et al. · Springer eBooks · 5

Impact of pre-operative serum C-reactive protein and cell-free chromatin levels on tumor aggressiveness and survival outcome in oral cavity squamous cell carcinoma

2020 · Hitesh R. Singhavi, Naveen Khare, et al. · Oral Oncology · 3

Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model.

2009 · PE Goss, VC Njar, et al. · Cancer Research · 3

27 INVITED Novel atypical retinoic acid metabolism blocking agents (RAMBAs)/ CYP26 inhibitors for breast cancer therapy

2008 · L.K. Gediya, P. Purushottamachar, et al. · European Journal of Cancer Supplements

Retinoic Acid Metabolism Blocking Agents (RAMBAs) for Treatment of Cancer and Dermatological Diseases

2006 · Vincent C. O. Njar, Lalji Gediya, et al. · ChemInform

Works count: 20

Citation count: 846

H-index: 12

I10-index: 13